Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

J Pharmacokinet Pharmacodyn · 2018 · PMC5953989 · PMID 29429038

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

No mayor differences were found in magnitude of parameter estimates or model fit, as expected (data not shown). NT-proBNP NT-proBNP did not demonstrate a clear trend over time during anthracycline or trastuzumab treatment and NT-proBNP concentrations did not increase before LVEF decline occurred and did not behave as an inverse of LVEF decline.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.